Nanobiotix to receive $1 million milestone after global trial expanded

French nanomedicine company Nanobiotix (Euronext: NANO–ISIN) says that its partner PharmaEngine will join its pivotal trial for NBTXR3 in soft tissue sarcoma to accelerate its development in the Asia-Pacific region.

Following the positive pilot Phase I results for advanced soft tissue sarcoma (STS) recently presented at the American Society of Clinical Oncology (ASCO) annual meeting, the planned European pivotal trial for NBTXR3 in soft tissue sarcoma will be broadened to Asia-Pacific where PharmaEngine will open additional clinical centers in multiple countries. Nanobiotix is sponsoring the global trial and PharmaEngine is co-sponsoring for the Asia-Pacific territory. The partners will bear the costs of the trial in their respective territories.

The expanded soft tissue sarcoma trial will provide additional clinical centers in multiples countries in Asia-Pacific, a larger cohort of enrolled patients and a more efficient study as Nanobiotix and PharmaEngine will share patient data. The companies say they hope this may lead to faster market approval in the Asia-Pacific region than originally anticipated. An ongoing pivotal trial in the Asia-Pacific region could also facilitate the pathway for other indications in this region due to the available clinical data from patients in soft tissue sarcoma.